PGS

PGS
Name	PGS
Specialty	Genetics
Acronyms	PGS
Field	Reproductive medicine
Related	Preimplantation genetic diagnosis, Assisted reproductive technology

PGS

PGS is a reproductive genetics procedure used in assisted reproduction to assess chromosomal status of embryos prior to uterine transfer. It aims to reduce implantation failure and miscarriage by identifying embryos with aneuploidies, integrating laboratory techniques from cytogenetics and molecular biology and interfacing with clinical pathways in IVF, obstetrics, and prenatal diagnostics. Major stakeholders include fertility clinics, genetic laboratories, regulatory bodies, and prospective parents.

Introduction

PGS emerged alongside innovations in in vitro fertilization and cytogenetic analysis, intersecting with advances in next-generation sequencing, fluorescence in situ hybridization, and array-based technologies. Historical milestones involve work at centers such as the Jones Institute for Reproductive Medicine and reports from groups affiliated with Harvard Medical School and University of California, San Francisco. Related clinical frameworks include protocols developed by societies like the American Society for Reproductive Medicine and the European Society of Human Reproduction and Embryology.

Terminology and Scope

The terminology surrounding PGS overlaps with terms introduced in literature and guidelines, including concepts developed in discussions at institutions such as Mayo Clinic and Johns Hopkins University. Distinctions are drawn between methods described in papers from Massachusetts General Hospital and nomenclature used by groups at Cleveland Clinic and Columbia University Irving Medical Center. Scope considerations reflect populations discussed in cohort studies at Stanford University and randomized trials led by teams at Imperial College London and University College London.

Methods and Technologies

Techniques used in PGS include blastomere biopsy approaches that were refined in work associated with Cornell University and trophectoderm biopsy protocols propagated by laboratories connected to Monash University and IVF Spain. Analytical technologies span fluorescence in situ hybridization studies first popularized in cytogenetics centers, comparative genomic hybridization developed in research at The Sanger Institute, single nucleotide polymorphism arrays used in facilities like Illumina-partnered labs, and next-generation sequencing platforms commercialized by companies such as Thermo Fisher Scientific and Illumina. Workflow integration often involves cryopreservation techniques linked historically to programs at McGill University and vitrification methods advanced at Yale School of Medicine. Quality control and accreditation frameworks draw on standards from organizations including College of American Pathologists and regional regulators such as the Human Fertilisation and Embryology Authority.

Clinical Applications and Outcomes

PGS has been applied in contexts described in clinical trials and observational series from centers like Mount Sinai Health System and Ronald Reagan UCLA Medical Center. Indications include advanced maternal age cohorts analyzed in multicenter studies from Mayo Clinic and recurrent pregnancy loss cases reported by investigators at Weill Cornell Medicine. Outcomes reported across literature vary: some randomized controlled trials from groups at Guy's and St Thomas' NHS Foundation Trust and Massachusetts General Hospital showed improved implantation rates, whereas meta-analyses incorporating data from Cochrane-affiliated reviews tempered early enthusiasm. Live-birth statistics and time-to-pregnancy metrics are frequently compared between protocols at reproductive centers such as Baylor College of Medicine and University of Pennsylvania Perelman School of Medicine.

Ethical, Legal, and Social Issues

Ethical debates around PGS have engaged scholars at Oxford University and Harvard Law School, and policy discussions have involved regulatory bodies like the European Commission and national ministries of health. Concerns include equity and access highlighted by analyses from World Health Organization forums, informed consent standards examined in casework at Stanford Law School, and societal implications considered in studies from Princeton University. Legal frameworks shaping practice draw on precedents in jurisdictions overseen by agencies such as the Food and Drug Administration and the Human Fertilisation and Embryology Authority, while bioethicists at institutions like Georgetown University have debated uses extending to non-disease trait selection discussed in commentary involving scholars from King's College London.

Limitations and Controversies

Limitations of PGS include mosaicism detection challenges reported in laboratory comparisons involving groups at Rijksuniversiteit Groningen and KU Leuven, false-positive and false-negative rates analyzed in methodological reviews from University of Cambridge teams, and procedural risks described in clinical safety reports from Vanderbilt University Medical Center. Controversies encompass debates about routine use summarized in position statements from the American Society for Reproductive Medicine and contested cost-effectiveness analyses authored by economists at London School of Economics and Harvard Business School. Ongoing research at centers including National Institutes of Health and Pasteur Institute aims to refine predictive value and integrate findings with prenatal diagnostic pathways led by perinatal groups at Erasmus University Medical Center.

Category:Genetics